Physician profile
Brooke Simpson
NPI 1306362678
$3,208.29
in general payments reported to CMS, 2019-2025
25 companies · $909 in 2025
The $909 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $291 · 2022: $591 · 2023: $660 · 2024: $758 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,326.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $529.01 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $443.98 | 2021-2025 | |
| Lilly USA, LLC | $398.23 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $379.76 | 2022-2025 | |
| Amgen INC. | $265.00 | 2021-2024 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $233.30 | 2021-2022 | |
| Exact Sciences Corporation | $202.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $129.93 | 2022-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $118.08 | 2022-2025 | Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $95.96 | 2022-2023 | |
| Rigel Pharmaceuticals, INC. | $64.09 | 2023 | Tavalisse, Rezlidhia |
| Merck Sharp & Dohme LLC | $50.64 | 2022-2024 | Capvaxive, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $49.27 | 2024 | Voquezna |
| Astellas Pharma US INC | $34.67 | 2021-2024 | Veozah |
| Actelion Pharmaceuticals US, INC. | $31.68 | 2024-2025 | Opsumit, Uptravi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.02 | 2022 | |
| Glaxosmithkline, LLC. | $21.27 | 2021 | |
| Axsome Therapeutics, INC. | $20.34 | 2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $19.28 | 2021 | |
| Esperion Therapeutics, INC. | $19.09 | 2021 | |
| Horizon Therapeutics Plc | $17.14 | 2022 | |
| Seqirus USA INC | $16.45 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Hikma Pharmaceuticals USA | $15.96 | 2023 | Mitigare, Ryaltris |
| Tolmar, INC. | $13.53 | 2025 | Jatenzo |
| Kowa Pharmaceuticals America, INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.